

Feds, Pharma Companies Strike Deal for Low Cost GLP-1 Medications

Healthcare Law Update

Feds, Pharma Companies Strike Deal for Low Cost GLP-1 Medications

John D. Fanburg
Managing Member & Chair, Healthcare

Richard B. Robins
Member, Healthcare

Andrew M. Kuder
Associate, Healthcare

BRACH | EICHLER LLC
Counsellors at Law

12/1/2025

On November 6, 2025, the Trump administration [announced](#) a landmark agreement with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to provide steep discounts on their most popular GLP-1 medications, cuts that will benefit Medicare and Medicaid enrollees as well as cash-paying patients. Under the agreement, prices for drugs like Ozempic, Wegovy, Zepbound, and future GLP-1 tablets will drop to an average of \$149 to \$350 per month, a dramatic decline from the current cost of \$500 to \$1,000 or more for many U.S. patients. The agreement delivers on a key goal of the current administration's Most-Favored-Nation (MFN) drug pricing initiative, which aims to bring U.S. prescription drug prices in line with, or below, those paid in other developed countries. The agreement is part of a broader administration strategy to end what it describes as "global freeloading"—where Americans pay far more for drugs than consumers in other countries.

Some highlights of the deal include: injectable GLP-1s like Ozempic and Wegovy will be available via the government's new TrumpRx purchasing platform at \$350 per month, down from \$1,000–\$1,350 per month; if approved, oral GLP-1 tablets (like Eli Lilly's orforglipron) will launch at around \$149 per month through TrumpRx; and, for Medicare beneficiaries, drugs like Wegovy and Zepbound will be covered for obesity under certain conditions and beneficiaries will pay just \$50 per month in co-pays. In addition to GLP-1 products, Eli Lilly will offer its Trulicity diabetes drug at \$389 per month, and Novo Nordisk will price its insulin products (like NovoLog and Tresiba) at \$35 per month.

The companies are also pledging to repatriate foreign revenues and guarantee MFN pricing on all future (and some existing) products, giving state Medicaid programs access to these lower, globally competitive drug costs. To support this effort, both companies are making significant U.S.-based investments. Novo Nordisk has committed to invest \$10 billion to expand domestic

production, including building capacity for a future Wegovy tablet, and Eli Lilly has committed \$27 billion to U.S. manufacturing infrastructure.

[Click Here to read the entire December 2025 Healthcare Law Update now!](#)

For more information, contact:

John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com

Richard B. Robins | 973.447.9663 | rrobins@bracheichler.com

Andrew M. Kuder | 973.403.3141 | akuder@bracheichler.com

Authors

The following attorneys contributed to this insight.



John D. Fanburg

Managing Member
Healthcare Law, Cannabis Industry

973.403.3107 · 973.618.5507 Fax

jfanburg@bracheichler.com



Richard B. Robins

Member
Healthcare Law, Litigation

973.447.9663 · 973.618.5977 Fax

rrobins@bracheichler.com



Andrew M. Kuder

Associate
Healthcare Law

973.403.3141 · 973.618.5955 Fax

akuder@bracheichler.com